The news is by your side.


U.S. FDA approves new drug for prevention of migraines

Amgen Inc won U.S. Food and Drug Administration approval on Thursday for the first drug in a new class designed to prevent migraine headaches in adults. The drug, Aimovig, which is given monthly by self-injection, will have a list price of $6,900 a year, or $575 a month, the company said. The price applies to both a 70 milligram and a 140 mg dose. Any discounts or rebates will depend on negotiations with health plans, Amgen spokeswoman Kristen Davis said. Some Wall Street analysts had expected a price as high as…